212 related articles for article (PubMed ID: 25850754)
1. Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.
Sailer V; Lüders C; Kuhn W; Pelzer V; Kristiansen G
Virchows Arch; 2015 Jul; 467(1):67-70. PubMed ID: 25850754
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
Rohilla M; Bal A; Singh G; Joshi K
Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
[TBL] [Abstract][Full Text] [Related]
3. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
4. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
5. The significance of combined CK5/6 and p63 immunohistochemistry in predicting the risks of subsequent carcinoma development in intraductal papilloma of the breast.
Yang Y; Suzuki K; Abe E; Li C; Uno M; Akiyama F; Yamauchi H; Kikuchi M; Ohde S; Deshpande G; Shibahara Y; Nakamura Y; Sasano H
Pathol Int; 2015 Feb; 65(2):81-8. PubMed ID: 25572436
[TBL] [Abstract][Full Text] [Related]
6. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.
Reisenbichler ES; Ross JR; Hameed O
Ann Diagn Pathol; 2014 Dec; 18(6):313-8. PubMed ID: 25224390
[TBL] [Abstract][Full Text] [Related]
7. P40 Immunostain Does Not Outperform p63 as a Myoepithelial Cell Marker in the Daily Practice of Breast Pathology.
Khazai L; Agosto-Arroyo E; Rosa M
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):599-604. PubMed ID: 28549030
[TBL] [Abstract][Full Text] [Related]
8. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
9. Head-to-Head Comparison of p63 and p40 in Non-Neuroendocrine Carcinomas of the Tubal Gut.
Bakhshwin AM; Gordon IO; Brown KB; Liu X; Allende DS
Int J Surg Pathol; 2020 Dec; 28(8):835-843. PubMed ID: 32466705
[TBL] [Abstract][Full Text] [Related]
10. Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.
Aguiar FN; Cirqueira CS; Bacchi CE; Carvalho FM
Breast Dis; 2015; 35(4):249-52. PubMed ID: 26397772
[TBL] [Abstract][Full Text] [Related]
11. Expression of p40 and laminin 332 in metaplastic spindle cell carcinoma of the breast compared with other malignant spindle cell tumours.
D'Alfonso TM; Ross DS; Liu YF; Shin SJ
J Clin Pathol; 2015 Jul; 68(7):516-21. PubMed ID: 25795733
[TBL] [Abstract][Full Text] [Related]
12. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
Ding Y; Ruan Q
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):405-7. PubMed ID: 17120733
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of p40 as a Myoepithelial Marker in Different Breast Lesions.
Kővári B; Szász AM; Kulka J; Marušić Z; Šarčević B; Tiszlavicz L; Cserni G
Pathobiology; 2015 Sep; 82(3-4):166-71. PubMed ID: 26330357
[TBL] [Abstract][Full Text] [Related]
14. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
15. Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy.
Collins BT; Wang JF; Bernadt CT
Acta Cytol; 2013; 57(6):619-24. PubMed ID: 24107322
[TBL] [Abstract][Full Text] [Related]
16. p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2014; 7(3):1032-41. PubMed ID: 24696720
[TBL] [Abstract][Full Text] [Related]
17. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.
Kriegsmann K; Cremer M; Zgorzelski C; Harms A; Muley T; Winter H; Kazdal D; Warth A; Kriegsmann M
Pathology; 2019 Apr; 51(3):240-245. PubMed ID: 30798982
[TBL] [Abstract][Full Text] [Related]
18. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast.
Kawaguchi K; Shin SJ
Am J Surg Pathol; 2012 Jul; 36(7):1009-20. PubMed ID: 22446941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
